| India Formulations | Branded generics across a wide range of therapies focused in India market | Largest field force in India, strong brand equity, wide portfolio | B2B and B2C through doctors, hospitals, pharmacies | Chronic therapies and specialty branded products | 173755 | 33 | Sales of prescription branded generics through extensive field force | Retail pricing and institutional tenders | Strong prescription brand presence, chronic therapy leadership, expanding doctor reach | Domperidone, Brufen, Levipil, Lenvima |
| United States Formulations | Innovative medicines, generics, dermatology, ophthalmology, oncology products | Integrated US manufacturing, extensive ANDA/NDA pipeline, strong dermatology presence | Healthcare providers, pharmacies, hospitals (B2B) | Innovative specialty medicines and complex generics | 170077 | 31 | Sales through commercial infrastructure, licensing, and partnerships | Direct sales with some licensing revenue | Innovative medicine launches, generic approvals, product pipeline expansion | Ilumya, Winlevi, Odomzo, Absorica, Cequa |
| Emerging Markets Formulations | Branded generics with focus on Russia, Romania, South Africa, Brazil, Mexico | Strong regional presence, localized manufacturing and sales network | Healthcare providers and pharmacies (B2B and B2C) | Specialty products and branded generics | 99560 | 18 | Sales via direct sales and distribution networks | Market-based pricing and local partnerships | Expanding market presence, local manufacturing, increasing healthcare demand | Various branded generics tailored to local markets |
| Rest of World Formulations | Innovative and generic medicines marketed in developed international markets | Strategic partnerships with local firms, strong innovative drug pipeline | Hospitals, pharmacies, healthcare providers (B2B) | Innovative medicines especially in dermatology and ophthalmology | 77020 | 14 | Sales via marketing partnerships and direct distribution | Licensing and direct sales | Licensing deals, innovative product launches in Europe, Canada, Japan | Cequa, Ilumya, Winlevi and other innovative and generic medicines |
| Active Pharmaceutical Ingredients (APIs) | Development, manufacturing and sale of active pharmaceutical ingredients | Integrated API manufacturing and approvals from global regulators | Pharmaceutical companies globally (B2B) | Specialty APIs for complex and regulated markets | 20900 | 4 | Sales to internal operations and third-party generic manufacturers | Contract manufacturing and supply agreements | Backward integration, regulatory approvals, supply reliability | Multiple APIs for in-house and external customers |
